Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

Recombinant RSV (Palivizumab Biosimilar) antibody

Reactivity: Human FACS, in vivo Host: Mouse Monoclonal unconjugated Recombinant Antibody
Catalog No. ABIN7200664
  • Target See all RSV (Palivizumab Biosimilar) products
    RSV (Palivizumab Biosimilar)
    Antibody Type
    Recombinant Antibody
    Reactivity
    Human
    Host
    • 1
    Mouse
    Clonality
    • 1
    Monoclonal
    Conjugate
    • 1
    This RSV (Palivizumab Biosimilar) antibody is un-conjugated
    Application
    Flow Cytometry (FACS), In vivo Studies (in vivo)
    Purpose
    Palivizumab Biosimilar, RSV Monoclonal Antibody
    Specificity
    The monoclonal antibody palivizumab biosimilar specifically binds to an epitope in the A antigenic site of the F protein of RSV (respiratory syncytial virus).
    Characteristics
    Recombinant Humanized IgG1 Monoclonal Antibody.
    Purification
    Protein A affinity column
    Purity
    > 95% by SDS-PAGE under reducing conditions and HPLC.
    Sterility
    0.2 μm filtered
    Endotoxin Level
    < 1 EU per 1 mg of the protein by the LAL method.
    Immunogen
    The monoclonal antibody palivizumab biosimilar was produced in the palivizumab biosimilar CHO stable cell line.
    Isotype
    IgG1 kappa
  • Application Notes
    ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by palivizumab.
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    PBS, pH 7.4, no stabilizers or preservatives.
    Preservative
    Without preservative
    Handling Advice
    Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
    Storage
    -20 °C
    Storage Comment
    12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied.
    Expiry Date
    12 months
  • Target
    RSV (Palivizumab Biosimilar)
    Abstract
    RSV (Palivizumab Biosimilar) Products
    Target Type
    Biosimilar
    Background
    Palivizumab, a humanized anti-RSV (respiratory syncytial virus) monoclonal antibody, targets an epitope in the A antigenic site of the F protein of RSV, inhibiting its entry into the cell and thereby preventing infection.
You are here:
Support